natgillin/translations-raw huggingface dataset:
I dette studie blev 358 patienter med inoperabelt, lokalt fremskreden SCCHN og WHO funktionsstatus 0 eller 1, randomiseret i en af to behandlingsarme.
In this study, 358 patients with inoperable locally advanced SCCHN, and WHO performance status 0 or 1, were randomised to one of two treatment arms.
Forekomsten af de følgende bivirkninger (alle grader): Letargi, stomatitis, neutropenisk infektion opstod  10 % oftere hos de patienter, som var 65 år eller derover end hos de yngre patienter.
The incidence of the following adverse events (all grades): lethargy, stomatitis, neutropenic infection occurred at rates  10% higher in patients who were 65 years of age or older compared to younger patients.
Fjern sprøjten, og bland miksturen manuelt ved at vende hætteglasset gentagne gange i mindst 45 sekunder.
Remove the syringe and needle and mix manually by repeated inversions for at least 45 seconds.
Der er observeret meget sjældne tilfælde af forbigående synsforstyrrelser (glimt, lysglimt, pletter i synsfeltet) typisk forekommende under infusion med lægemidlet og i forbindelse med overfølsomheds-reaktioner.
Very rare cases of transient visual disturbances (flashes, flashing lights, scotomata) typically occurring during infusion of the medicinal product and in association with hypersensitivity reactions have been reported.
Reaktiner på infusionsstedet; Smerter
Infusion site reaction; Pain
(521 patienter i FAC-armen) som adjuverende behandling.
(539 patients in TAC arm), or doxorubicin
Hyppigheden af relateret feber, diarré, anoreksi og perifere ødemer var  10 % højere hos patienter som var 75 år eller ældre end hos patienter under 65 år.
The incidence of related fever, diarrhoea, anorexia, and peripheral oedema occurred at rates  10% higher in patients who were 75 years of age or greater versus less than 65 years.
Det primære endepunkt i dette studie, progression-fri overlevelse (PFS), var signifikant længere i TPF-armen sammenlignet med PF-armen, p = 0,0042 (median PFS: 11,4 vs. 8,3 måneder respektivt) med en samlet median opfølgningstid på 33,7 måneder.
The primary endpoint in this study, progression-free survival (PFS), was significantly longer in the TPF arm compared to the PF arm, p = 0.0042 (median PFS: 11.4 vs. 8.3 months respectively) with an overall median follow up time of 33.7 months.
4.1.3 Injicer hele indholdet fra sprøjten i det tilsvarende TAXOTERE-hætteglas.
4.1.3 Inject the entire contents of the syringe into the corresponding TAXOTERE vial.
Sygdoms-fri overlevelse (DFS) var det primære effektendepunkt og total overlevelse (OS) var det sekundære effektendepunkt.
Disease-free survival (DFS) was the primary efficacy endpoint and Overall survival (OS) was the secondary efficacy endpoint.
2-års overlevelse (%)
2-year Survival (%)
256 patienter blev randomiseret til behandling med docetaxel alene (100 mg/ m som 1 times intravøs infusion hver 3. uge).
256 patients were randomised to treatment with docetaxel alone (100 mg/m as a 1 hour intravenous infusion every 3 weeks).
• Hævelse forårsaget af mangelfuld lymfeafløb
• swelling caused by faulty lymphatic drainage
Responseratio variabler: Fisher's Exact test * p-værdi for beskrivende formål **PSA response: Prostata-specifik antigen respons: PSA niveau <0,2 ng/ml målte to på hinanden følgende målinger med mindst 4 ugers mellemrum.
** PSA response: Prostate-Specific Antigen response: PSA level <0.2 ng/mL measured for two consecutive measurements at least 4 weeks apart.
Sygdoms-fri overlevelse
Disease Free Survival
Alvorlige hudproblemer såsom, Stevens-Johnson syndrom (SJS), toksisk epidermal nekrolyse (TEN) og akut generaliseret eksantematøs pustulose (AGEP) er blevet rapporteret med TAXOTERE: - SJS/TEN symptomer kan omfatte blærer, afskrælning eller blødning på dele af huden (herunder dine læber, øjne, mund, næse, kønsorganer, hænder eller fødder) med eller uden udslæt.
Severe skin problems such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Acute Generalized Exanthematous Pustulosis (AGEP) have been reported with TAXOTERE: - SJS/TEN symptoms may include blistering, peeling or bleeding on any part of your skin (including your lips, eyes, mouth, nose, genitals, hands or feet) with or without a rash.
• Infektion i de øvre luftveje.
• infection of the upper respiratory tract.
4.2.1 Det kan være nødvendigt at anvende mere end et hætteglas præmix for at opnå den dosis, der er nødvendig til patienten.
4.2.1 More than one premix vial may be necessary to obtain the required dose for the patient.
Milde til moderate neurosensoriske symptomer er karakteriseret ved paræstesi, dysæstesi eller smerter inklusiv brændende fornemmelser.
Mild to moderate neuro-sensory signs are characterised by paresthesia, dysesthesia or pain including burning.
0,5 ml (påfyldt 0,61 ml)
0.5 ml (Fill 0.61 ml)
Klar for tilsætning til infusionsvæske.
Ready to add to infusion solution.
Gastrointestinal Hæmoragi (alvorlig:
Gastrointestinal haemorrhage (severe:
Se også punktet ”TAXOTERE indeholder ethanol (alkohol)” nedenfor.
See also section “TAXOTERE contains ethanol (alcohol)” below.
Hjertesvigt er observeret hos patienter, som fik docetaxel i kombination med trastuzumab, specielt efter kemoterapi med anthracycline (doxorubicin eller epirubicin).
Heart failure has been observed in patients receiving docetaxel in combination with trastuzumab, particularly following anthracycline (doxorubicin or epirubicin)-containing chemotherapy.
• Præmix-opløsning: Præmix-opløsningen indeholder 10 mg/ml docetaxel og skal bruges straks efter tilberedning.
• Premix solution: The premix solution contains 10 mg/ml docetaxel and should be used immediately after preparation.
Ikke anvendt lægemiddel samt affald heraf skal bortskaffes i overensstemmelse med lokale retningslinjer.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Det er vigtigt at læse hele indholdet af denne vejledning inden fremstilling af enten TAXOTERE præmix-opløsningen eller TAXOTERE infusionsvæske
It is important that you read the entire contents of this guide prior to the preparation of either the TAXOTERE premix solution or the TAXOTERE infusion solution
Docetaxel er et antineoplastisk lægemiddel og, som med andre potentielt giftige lægemidler, skal der udvises forsigtighed under håndtering og tilberedning af opløsninger heraf.
Docetaxel is an antineoplastic agent and, as with other potentially toxic compounds, caution should be exercised when handling it and preparing its solutions.
Gastrisk adenokarcinom Den anbefalede dosis af docetaxel er 75 mg/m som en 1-times infusion, efterfulgt af cisplatin
Gastric adenocarcinoma The recommended dose of docetaxel is 75 mg/m as a 1-hour infusion, followed by cisplatin
Flere grad 3/4 bivirkninger blev observeret for TAXOTERE monoterapi (55,4 %) sammenlignet med paclitaxel (23,0 %).
More grade 3/4 adverse events were observed for docetaxel monotherapy (55.4%) compared to paclitaxel (23.0%).
Følgende allergiske reaktioner (kan forekomme hos flere end 1 ud af 10 patienter) kan optræde under infusionen på hospitalet:
During the infusion at the hospital the following allergic reactions may occur (may affect more than 1 in 10 people):
Lokoregional behandling med stråling blev givet enten med en konventionel fraktion (1,8 Gy-2,0 Gy en gang daglig, 5 dage om ugen til en total dosis på 66 til 70 Gy), eller accelererede/hyperfraktionerede regimer af strålebehandling (to gange daglig, med et minimum interfraktion-interval på 6 timer, 5 dage pr. uge).
Locoregional therapy with radiation was delivered either with a conventional fraction (1.8 Gy - 2.0 Gy once a day, 5 days per week for a total dose of 66 to 70 Gy), or accelerated/hyperfractionated regimens of radiation therapy (twice a day, with a minimum interfraction interval of 6 hours, 5 days per week).
Tal med din læge, hvis du lider af alkohol afhængighed, epilepsi eller sygdomme i leveren.
Discuss with your doctor if you suffer from alcohol dependency, epilepsy or liver impairment.
Efter den sidste cyklus af kemoterapi, fik patienter i begge arme, der havde positive østrogen- og/eller progesteron-receptorer tamoxifen 20 mg daglig i op til 5 år.
In both arms, after the last cycle of chemotherapy, patients with positive eostrogen and/or progesterone receptors received tamoxifen 20 mg daily for up to 5 years.
Docetaxel øgede responsraten (33 % mod 12 %, p < 0,0001), forlængede tiden til progression (19 uger mod 11 uger, p = 0,0004), samt forlængede overlevelsen (11 måneder mod 9 måneder, p = 0,01).
Docetaxel increased response rate (33% vs. 12%, p < 0.0001), prolonged time to progression (19 weeks vs. 11 weeks, p = 0.0004) and prolonged overall survival (11 months vs. 9 months, p = 0.01).
In vitro-studier har vist, at docetaxels metabolisme kan ændres ved samtidig medicinering med stoffer, som inducerer, hæmmer eller metaboliseres (og således hæmmer enzymet kompetitivt) af CYP3A, f.eks ciclosporin, ketoconazol og erythromycin.
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds which induce, inhibit or are metabolised by (and thus may inhibit the enzyme competitively) cytochrome P450-3A such as ciclosporine, ketoconazole and erythromycin.
Patienter, som får grad 3- eller 4-stomatitis, bør have deres dosis reduceret til 60 mg/m
Patients who experience Grade 3 or 4 stomatitis should have their dose decreased to 60 mg/m².
Efter administration af docetaxel 100 mg/m givet som infusion over 1 time, fandtes den gennemsnitlige maksimale plasmakoncentration at være 3,7 mg/ml med et AUC på 4,6 h.g/ml.
Following the administration of a 100 mg/m dose given as a one-hour infusion a mean peak plasma level of 3.7 µg/ml was obtained with a corresponding AUC of 4.6 h.µg/ml.
Blandt de patienter, der fik docetaxel hver tredje uge, var hyppigheden af relaterede negleforandringer  10 % højere i patientgruppen på 65 år og derover, end i gruppen af yngre patienter.
In patients treated with docetaxel every three weeks, the incidence of related nail changes occurred at a rate  10% higher in patients who were 65 years of age or greater compared to younger patients.
Docetaxel+standardpleje
Docetaxel + standard of care Standard of care alone
Med en hazard ratio < 1 kan docetaxel + cisplatin+5-FU anvendes med fordel * Ujusteret log-rank test ** Ujusteret log-rank test, ikke justeret efter multipel sammenligning *** Chi-square-test, ikke justeret for multipel sammenligning NA: Not Applicable
A hazard ratio of less than 1 favours docetaxel + cisplatin + fluorouracil *un-adjusted log-rank test **un-adjusted log-rank test, not adjusted for multiple comparisons ***Chi square test, not adjusted for multiple comparisons NA-not applicable
I et fase III-studie med tidligere behandlede patienter var tid til progression (12,3 uger vs. 7 uger) og den samlede overlevelse signifikant længere for docetaxel ved doseringen 75 mg/m end for bedste palliative behandling.
In a phase III study, in previously treated patients, time to progression (12.3 weeks versus 7 weeks) and overall survival were significantly longer for docetaxel at 75 mg/m² compared to Best Supportive Care.
4.1.4 Fjern sprøjten og bland miksturen manuelt ved at vende hætteglasset gentagne gange i mindst 45 sekunder.
4.1.4 Remove the syringe and needle and mix manually by repeated inversions for at least 45 seconds.
I kombination med trastuzumab er den anbefalede dosis af docetaxel 100 mg/m hver 3. uge med en ugentlig administration af trastuzumab.
In combination with trastuzumab the recommended dose of docetaxel is 100 mg/m every three weeks, with trastuzumab administered weekly.
BEMÆRK: Udtag den nødvendige mængde af dette docetaxel koncentrat (20 mg/ml) fra hætteglasset og tilsæt det direkte til infusionsvæsken.
CAUTION: Withdraw the required amount of this docetaxel concentrate (20 mg/ml) from the vial and add it directly into the infusion solution.
BEMÆRK: Skal fortyndes med hele indholdet fra hætteglasset med solvens.
CAUTION: Dilution required with the entire contents of the solvent vial.
For behandling efter forudgående svigt af platinbaseret kemoterapi, er den anbefalede dosis 75 mg/m givet som enkeltstof.
For treatment after failure of prior platinum-based chemotherapy, the recommended dose is 75 mg/m² as a single agent.
Median overlevelse i alt var også signifikant længere til fordel for TPF-armen sammenlignet med PF-armen (median OS: 18,6 vs. 14,5 måneder respektivt) med en 28 % reduktion af risikoen for død, p = 0,0128.
Median overall survival was also significantly longer in favour of the TPF arm compared to the PF arm (median OS: 18.6 vs. 14.5 months respectively) with a 28% risk reduction of mortality, p = 0.0128.
I tilfælde af efterfølgende episoder med kompliceret neutropeni, bør dosis af docetaxel reduceres fra 60 mg/m til 45 mg/m 2.
If subsequent episodes of complicated neutropenia occur the docetaxel dose should be reduced from 60 to 45 mg/m2.
I kombination med capecitabin er de mest almindelige behandlingsrelaterede bivirkninger ( 5 %), som blev rapporteret i et fase III-studium med brystkræftpatienter, hvor anthracyclinbehandling ikke havde haft effekt, medtaget (se: Produktresuméet for capecitabin).
For combination with capecitabine, the most frequent treatment-related undesirable effects (≥ 5%) reported in a phase III study in breast cancer patients failing anthracycline treatment are presented (see capecitabine summary of product characteristics).
I patienter, som var 75 år eller ældre, blev der rapporteret en højere forekomst af neutropeni, anæmi, diarré, dyspnø, og infektioner i de øvre luftveje, sammenlignet med yngre patienter (mindst 10 % højere).
In patients who were 75 years of age or older, when compared to younger patients, neutropenia, anaemia, diarrhea, dyspnea and upper respiratory tract infection were reported with a greater incidence (at least 10% higher).
TAXOTERE som enkeltstof
TAXOTERE as single agent
Uden at påvirke overlevelsestiden (docetaxel 15 måneder mod doxorubicin 14 måneder, p = 0,38) eller tiden til progression (docetaxel 27 uger mod doxorubicin 23 uger, p = 0,54), øgede docetaxel responsraten (52 % mod 37 %, p = 0,01) og gav hurtigere respons (12 uger mod 23 uger, p = 0,007).
Without affecting overall survival time (docetaxel 15 months vs. doxorubicin 14 months, p = 0.38) or time to progression (docetaxel 27 weeks vs. doxorubicin 23 weeks, p = 0.54), docetaxel increased response rate (52% vs. 37%, p = 0.01) and shortened time to response (12 weeks vs. 23 weeks, p = 0.007).
Du kan også have influenalignende symptomer på samme tid, såsom feber, kulderystelser eller ømme muskler.)
You may also have flu-like symptoms at the same time, such as fever, chills or aching muscles.)
Patienterne havde operabel, lymfeknude-negativ brystkræft med høj risiko for tilbagefald ifølge 1998 St. Gallen-kriterierne (tumorstørrelse > 2 cm og/eller negative østrogenreceptorer (ER) og progesteronreceptorer (PR) og/eller høj histologisk/nukleær grad (grad 2 til 3) og/eller alder < 35 år).
FAC arm), as adjuvant treatment of operable node-negative breast cancer patients with high risk of relapse according to 1998 St. Gallen criteria (tumour size >2 cm and/or negative ER and PR and/or high histological/nuclear grade (grade 2 to 3) and /or age <35 years).
• Nedsat indhold af natrium og/eller magnesium i blodet (forstyrrelse i elektrolytbalancen).
• decrease of the sodium and/or magnesium in your blood (electrolyte balance disorders)
I studiet TAX 316 oplevede 26 patienter (3,5%) i TAC-armen og 17 patienter (2,3%) i FAC-armen kongestivt hjertesvigt.
In study TAX316, 26 patients (3.5%) in the TAC arm and 17 patients (2.3%) in the FAC arm experienced congestive heart failure.
Livskvalitetsparametre
Quality of life parameters
I kombinationer med androgen deprivationsbehandling og med prednison eller prednisolon (STAMPEDE studie) præsenteres bivirkninger, der forekommer i de 6 cyklusser af behandlingen med docetaxel og med mindst 2 % højere forekomst i docetaxel-behandlingsarmen, til sammenligning med kontrolarmen, under anvendelse af CTCAE-klasseficeringskalaen.
For combination with ADT and with prednisone or prednisolone (STAMPEDE study), adverse events occurring occurring over the 6 cycles of treatment with docetaxel and having at least 2% higher incidence in the docetaxel treatment arm by comparison to the control arm, are presented, using the CTCAE grading scale.
Præ-menopausal
Post-Menopausal
Hvis du er mand i behandling med TAXOTERE, rådes du til ikke at avle et barn under og 6 måneder efter behandling samt til at søge vejledning om opbevaring af sæd inden behandling, fordi docetaxel kan nedsætte den mandlige fertilitet.
If you are a man being treated with TAXOTERE you are advised not to father a child during and up to 6 months after treatment and to seek advice on conservation of sperm prior to treatment because docetaxel may alter male fertility.
Det er vigtigt at læse hele denne vejledning inden fremstilling af TAXOTERE infusionsvæske.
It is important that you read the entire contents of this guide prior to the preparation of the TAXOTERE infusion solution.
Injicer hele indholdet af sprøjten i det tilsvarende hætteglas med TAXOTERE.
Inject the entire contents of the syringe into the corresponding TAXOTERE vial.
4.1 Fremstilling af TAXOTERE præmix-opløsning (10 mg docetaxel/ml)
4.1 Preparation of the TAXOTERE premix solution (10 mg docetaxel/ml)
CYTOTOKSISK
CYTOTOXIC
Docetaxel infusionsvæske er overmættet, den kan derfor udkrystallisere over tid.
Docetaxel infusion solution is supersaturated, therefore may crystallize over time.
• Infusionsopløsning: Infusionsopløsningen skal bruges inden for 4 timer ved stuetemperatur (under 25°C).
• Infusion solution: the infusion solution should be used within 4 hours at room temperature (below 25°C).
Forsigtighedsregler for anvendelse ved adjuverende behandling af brystkræft Der er begrænsede tilgængelige data vedrørende anvendelse af docetaxel i kombination med doxorubicin og cyclophosphamid til patienter over 70 år.
Cautions for use in adjuvant treatment of breast cancer There are limited data available in patients > 70 years of age on docetaxel use in combination with doxorubicin and cyclophosphamide.
Med docetaxel er der rapporteret tilfælde af kutan lupus erythematosus, bulløst udslæt såsom erythema multiforme og alvorlige kutane bivirkninger såsom Stevens-Johnson syndrom, toksisk epidermal nekrolyse og akut generaliseret eksantematøs pustulose.
Cases of cutaneous lupus erythematosus, bullous eruptions such as erythema multiforme and severe cutaneous adverse reactions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis
En dosis på 140 mg docetaxel kræver f.eks. 7 ml docetaxel koncentrat til infusionsvæske.
For example, a dose of 140 mg docetaxel would require 7 ml docetaxel concentrate for solution.
Ved kombination med docetaxel, var carboplatins clearence ca. 50 % højere end de værdier, der tidligere er rapporteret for carboplatin-monoterapi.
When combined to docetaxel, the clearance of carboplatin was about 50% higher than values previously reported for carboplatin monotherapy.
• Blodpropper.
• blood clots.
TAC = docetaxel, doxorubicin og cyclophosphamid FAC = 5-fluoruracil, doxorubicin and cyclophosphamid CI = Konfidensinterval; ER = østrogenreceptor PR = progesteronreceptor a
TAC = docetaxel, doxorubicin and cyclophosphamide FAC = 5-fluorouracil, doxorubicin and cyclophosphamide CI = confidence interval; ER = eostrogen receptor PR = progesterone receptor a
• 1.276 patienter (744 i TAX 316 og 532 i GEICAM 9805), som fik docetaxel i kombination med doxorubicin og cyclophosphamid (bivirkninger til klinisk vigtig behandling er præsenteret).
• 1276 patients (744 and 532 in TAX 316 and GEICAM 9805 respectively) who received docetaxel in combination with doxorubicin and cyclophosphamide (clinically important treatment related adverse events are presented).
Almene symptomer og reaktioner på administrationsstedet Den mediane kumulative dosis til behandlingsophør var mere end 1000 mg/m og median-tiden til reversibilitet af væskeretention var 16,4 uger (range 0 til 42 uger).
General disorders and administration site conditions The median cumulative dose to treatment discontinuation was more than 1,000 mg/m and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks).
I dette kliniske studium randomiseredes 255 patienter til behandling med docetaxel (75 mg/m² som en 1-times intravenøs infusion hver 3. uge) og capecitabin (1250 mg/m to gange daglig i 2 uger efterfulgt af en uges pause).
In this study, 255 patients were randomised to treatment with docetaxel (75 mg/m as a 1 hour intravenous infusion every 3 weeks) and capecitabine (1250 mg/m twice daily for 2 weeks followed by 1-week rest period).
Forsigtighedsregler ved behandling af gastrisk adenokarcinom Blandt 300 patienter (221 patienter i fase III-delen af studiet og 79 patienter i fase II-delen af studiet), som fik behandling med docetaxel i kombination med cisplatin og 5-fluoruracil i studiet af gastrisk kræft, var 74 patienter 65 år eller ældre og 4 patienter var 75 år eller ældre.
Cautions for use in gastric adenocarcinoma cancer Among the 300 (221 patients in the phase III part of the study and 79 patients in the phase II part) patients treated with docetaxel in combination with cisplatin and 5-fluorouracil in the gastric cancer study, 74 were 65 years of age or older and 4 patients were 75 years of age or older.
Gennemsnitsværdierne for den totale clearence og steady-state distributionsvolumen var henholdsvis 21 l/h/m og 113 l. Den interindividuelle variation i totalclearance var ca 50 %.
Mean values for total body clearance and steady-state volume of distribution were 21 l/h/m and 113 l, respectively.
Menopausal status
Menopausal status Pre-Menopausal
• Følelsesløshed eller stikkende og prikkende fornemmelse eller smerter i muskelfæster
• feeling of numbness or pins and needles or pain in the joints or muscles
• Ved behandling af prostatakræft kan TAXOTERE indgives i kombination med prednison eller prednisolon.
- For the treatment of prostate cancer, TAXOTERE is administered in combination with prednisone or prednisolone.
Febril neutropeni (G3-4: 15%)
Febrile neutropenia (G3-4: 15%)
TAXOTERE i kombination med doxorubicin og cyclophosphamid: Adjuverende behandling
TAXOTERE in combination with doxorubicin and cyclophosphamide: adjuvant therapy
Docetaxel-infusionsvæsken er overmættet, den kan derfor udkrystallisere over tid.
Docetaxel infusion solution is supersaturated, therefore may cristallize over time.
Skal gives under vejledning af en læge med erfaring i behandling med cytostatika.
To be administered under the supervision of a physician experienced in the use of cytotoxic agents.
TAXOTERE i kombination med capecitabin
TAXOTERE in combination with capecitabine
INSTRUKTIONER VEDRØRENDE SIKKER HÅNDTERING
RECOMMENDATIONS FOR THE SAFE HANDLING
PSA respons** ved 6 måneder - N(%) p-værdia*
PSA response** at 6 months - N(%) p-valuea*
Der var en forøget forekomst af meget alvorlige bivirkninger (40 % mod 31 %) og grad 4 alvorlige bivirkninger (34 % mod 23 %) i kombinationsarmen trastuzumab sammenlignet med docetaxel enkeltbehandling.
There was an increased incidence of SAEs (40% vs. 31%) and Grade 4 AEs (34% vs. 23%) in the trastuzumab combination arm compared to docetaxel monotherapy.
Du kan også have influenzalignende symptomer på samme tid, så som feber, kulderystelser eller ømme muskler.
You may also have flu-like symptoms at the same time, such as fever, chills or aching muscles.
G3/4 ALAT forhøjet
G3/4 AST increased
Fase I-studier har undersøgt docetaxels farmakokinetiske egenskaber hos kræftpatienter efter indgift af 20- 115 mg/m2.
The pharmacokinetics of docetaxel have been evaluated in cancer patients after administration of 20-115 mg/m in phase I studies.
• Hvert hætteglas er til engangsbrug og bør anvendes straks efter anbrud.
• Each vial is for single use and should be used immediately after opening.